Profile data is unavailable for this security.
About the company
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
- Revenue in USD (TTM)313.00k
- Net income in USD-16.74m
- Incorporated2000
- Employees16.00
- LocationNotable Labs Ltd320 Hatch DriveFOSTER CITY 94404United StatesUSA
- Phone+1 (415) 851-2410
- Fax+972 8993-5001
- Websitehttps://notablelabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 99.96k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
Health Advance Inc | -100.00bn | -100.00bn | 122.62k | 3.00 | -- | 0.0284 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
Seelos Therapeutics Inc | 2.01m | 4.09m | 170.02k | 8.00 | 0.002 | -- | -- | 0.0844 | 156.15 | 156.15 | 22.91 | -135.50 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
Notable Labs Ltd | 313.00k | -16.74m | 172.90k | 16.00 | -- | 0.0215 | -- | 0.5524 | -2.47 | -2.47 | 0.046 | 0.7439 | 0.0176 | -- | -- | 19,562.50 | -93.89 | -52.02 | -120.26 | -62.09 | 37.70 | 60.19 | -5,346.97 | -3,636.93 | -- | -- | 0.0405 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
Propanc Biopharma Inc | 0.00 | -1.87m | 236.97k | 1.00 | -- | -- | -- | -- | -0.0372 | -0.0372 | 0.00 | -0.006 | 0.00 | -- | -- | -- | -1,495.00 | -4,082.63 | -- | -- | -- | -- | -- | -- | -- | -2.55 | -- | -- | -- | -- | 35.61 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
UBS Securities LLCas of 30 Sep 2024 | 36.00k | 0.37% |
Geode Capital Management LLCas of 30 Sep 2024 | 19.54k | 0.20% |
Two Sigma Securities LLCas of 30 Sep 2024 | 15.27k | 0.16% |
FNY Capital Management LPas of 30 Sep 2024 | 10.00k | 0.10% |
BNP Paribas Financial Marketsas of 30 Sep 2024 | 2.20k | 0.02% |
Group One Trading LLCas of 30 Sep 2024 | 1.27k | 0.01% |
Morgan Stanley & Co. LLCas of 30 Sep 2024 | 800.00 | 0.01% |
Tower Research Capital LLCas of 30 Sep 2024 | 417.00 | 0.00% |
Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 229.00 | 0.00% |
Desjardins Securities, Inc.as of 30 Sep 2024 | 115.00 | 0.00% |